secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0000950170-24-065229
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma appoints new CFO, shareholders approve share increase and reverse split authority
--------------------------------------------------------------------------------

- Mark A. Kowieski appointed CFO effective May 22, 2024; annual base salary $390,000, target bonus 40%.
- CEO Matthew D'Onofrio base salary raised to $615,000, target bonus to 60%.
- Shareholders approved increase in authorized common shares from 50M to 100M.
- Shareholders approved amendment to 2013 Equity Incentive Award Plan, adding 4M shares plus evergreen provision (up to 6% of outstanding annually).
- Shareholders granted Board authority to effect reverse stock split within 1 year, range 1:2 to 1:20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/0000950170-24-065229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/evok-20240522.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-065229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer